Table 2.
Symptomatic remission rates during follow-up (mITT efficacy analysis set)
| Time point | Asian subgroup (n = 70) | South Korea (n = 32) | Malaysia (n = 21) | Taiwan (n = 17) | Overall study (n = 303) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
||||||||||
| n (%) | 95% CI | n (%) | 95% CI | n (%) | 95% CI | n (%) | 95% CI | n (%) | 95% CI | |||||
| Month 6 | 46 (66.7) | 54.3−77.6 | 21 (65.6) | 46.8−81.4 | 13 (65.0) | 40.8−84.6 | 12 (70.6) | 44.0−89.7 | 148 (49.8) | 44.0−55.7 | ||||
| Month 9 | 49 (71.0) | 58.8−81.3 | 23 (71.9) | 53.3−86.3 | 14 (70.0) | 45.7−88.1 | 12 (70.6) | 44.0−89.7 | 166 (56.7) | 50.8−62.4 | ||||
| Month 12 | 50 (73.5) | 61.4−83.5 | 23 (74.2) | 55.4−88.1 | 15 (75.0) | 50.9−91.3 | 12 (70.6) | 44.0−89.7 | 171 (59.2) | 53.3−64.9 | ||||
| LOCF | 50 (71.4) | 59.4−81.6 | 23 (71.9) | 53.3−86.3 | 15 (71.4) | 47.8−88.7 | 12 (70.6) | 44.0−89.7 | 172 (56.8) | 51.0−62.4 | ||||
Percentages were calculated based on the number of patients with available data.
LOCF, last observation carried forward; mITT, modified intent-to-treat.